What I have: a GLP-1 receptor agonist · 0.9% sodium chloride.
I can find plenty of assertions about this and almost no reasoning, which is usually a sign that nobody has checked.
Assume no laboratory access beyond what I can pay a third party for.
Concretely, what should I do, and how would I know afterwards whether I did it right?
0.9 per cent is 9 mg of sodium chloride per millilitre — 0.9 g in 100 mL — which works out at about 154 mmol/L of each ion and is why it is called isotonic. The number that sets a beyond-use date is not the tonicity, though: it is the absence of a preservative. Plain 0.9 per cent sodium chloride for injection is single-use, so a compounded preparation made in it is dated on sterility grounds long before chemistry becomes the limit. Bacteriostatic diluents carry benzyl alcohol and buy the twenty-eight days the convention describes; 9 mg/mL of salt buys none of it. A beyond-use date set on stability data alone, with no sterility argument behind it, is a date about the molecule and not about the vial.
The honest answer is that a well-run compounding pharmacy is a serious operation and that the variance across facilities is wide.
Compounding is the preparation of a medicine for an individual patient in response to a prescription, where an approved product is unsuitable. It sits outside the approval framework by design rather than by omission.
Regulators generally prohibit compounding what is essentially a copy of a commercially available product, with a shortage listing being the usual exception that permits it temporarily.
Compounding is defined in regulation as preparation for an individual patient under prescription and is distinguished from manufacturing by scale and by the patient-specific requirement.
Check the beyond-use date and what it was based on.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsStated carefully, the relevant distinction is between compounding for an individual patient and compounding at scale, which are regulated differently.
Additives are the other divergence. Preparations combining an active with vitamins or other agents are not equivalent to the approved product and have not been studied in that combination.
Ask for the certificate of analysis on the compounded lot. A serious facility will have one; the request itself is informative.
Ask which salt form. A different salt is a different active moiety.
The short version: legitimate under a prescription within defined limits, unapproved by definition, and quality depends entirely on the facility.
Salt forms matter: a compounded preparation using a different salt from the approved product is not the same active moiety, and that has been the specific object of regulatory warnings.
On the detail: beyond-use dates on compounded sterile preparations are set by standards that depend on the preparation environment and are much shorter than a manufactured product's shelf life.
Ask for the certificate of analysis on the lot. A serious facility has one.
This is an area where the legal position and the quality question are separate and both matter.
A compounded preparation has no marketing authorisation, no batch release by a qualified person and no pharmacovigilance obligation attached to it. That is the structural difference from a licensed product.
Regulatory warnings have specifically addressed salt forms differing from the approved active moiety in this therapeutic area.
The framework is jurisdiction-specific. Check yours rather than a general answer.
Start with the regulatory basis, because compounding is permitted under specific conditions and those conditions are the whole subject.
Facility quality varies enormously and is the practical determinant of what you receive. The relevant questions are about sterility assurance, potency testing and beyond-use dating.
The caveat is that the legal and regulatory position differs by jurisdiction and nothing here is legal advice.
Compounded means unapproved by definition. That is structural, not pejorative.
edited 12 Mar 2025 by nynke_dekker — removed a claim I could not source
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.